US 9254262
Dosage and formulation
granted A61KA61K31/167A61K31/439
Quick answer
US patent 9254262 (Dosage and formulation) held by Almirall, S.A. expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Almirall, S.A.
- Grant date
- Tue Feb 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K31/167, A61K31/439, A61K31/46, A61K31/58